Ocugen (OCGN) Assets Average (2015 - 2026)
Ocugen's (OCGN) quarterly Assets Average came in at $50.2 million in Q1 2026, down 31.64% YoY from $73.5 million in Q1 2025, and down 0.68% on a QoQ basis from $50.6 million in Q4 2025.
Ocugen (OCGN) Assets Average (2015 - 2026) Analysis & Trends
Ocugen (OCGN) has 12 years of Assets Average data on file, last reported at $50.2 million in Q1 2026.
- Quarterly Assets Average fell 31.64% year-over-year to $50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.2 million (down 31.64% YoY) and the FY2025 annual result came in at $63.0 million, down 14.31% from the prior year.
- Assets Average fell to $50.2 million in Q1 2026, from $50.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $135.9 million in Q2 2022 to a low of $46.2 million in Q2 2024.
- A 5-year average of $79.9 million and a median of $72.2 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average surged 204.7% — and 2024, when it tumbled 50.16%.
- Tracing OCGN's Assets Average over 5 years: stood at $112.4 million in 2022, then sank by 38.08% to $69.6 million in 2023, then grew by 3.69% to $72.2 million in 2024, then declined by 29.97% to $50.6 million in 2025, then retreated by 0.68% to $50.2 million in 2026.
- The last three Assets Average figures came in at $50.2 million (Q1 2026), $50.6 million (Q4 2025), and $55.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | 90.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.56 Mn |
| Mar 31, 2026 | 50.21 Mn |
| Dec 31, 2025 | 50.56 Mn |
| Sep 30, 2025 | 55.60 Mn |
| Jun 30, 2025 | 59.03 Mn |
| Mar 31, 2025 | 73.45 Mn |
| Dec 31, 2024 | 72.19 Mn |
| Sep 30, 2024 | 51.24 Mn |
| Jun 30, 2024 | 46.17 Mn |
| Mar 31, 2024 | 58.17 Mn |
| Dec 31, 2023 | 69.62 Mn |
| Sep 30, 2023 | 81.83 Mn |
| Jun 30, 2023 | 92.64 Mn |
| Mar 31, 2023 | 102.47 Mn |
| Dec 31, 2022 | 112.44 Mn |
| Sep 30, 2022 | 123.16 Mn |
| Jun 30, 2022 | 135.91 Mn |
| Mar 31, 2022 | 123.74 Mn |
| Dec 31, 2021 | 111.04 Mn |
| Sep 30, 2021 | 120.28 Mn |